At the news
? NEUTRALIMPACT 5/10 8-K filed Nov 12, 2026 at 07:31 ET
Vor Biopharma expanded its license agreement with RemeGen to include RC298, a next-generation dual BAFF/APRIL inhibitor, for development outside Greater China. Vor Bio paid $10M cash and issued a pre-funded warrant for 2.3M shares (valued at ~$46M) as upfront consideration, with up to $300M in additional development milestones. The deal strengthens Vor Bio's autoimmune pipeline but adds dilution and cash outlay.
- Vor Bio and RemeGen entered an amended license agreement adding RC298, a next-gen dual BAFF/APRIL inhibitor, to the existing telitacicept franchise.
- Upfront consideration: $10M cash + pre-funded warrant to purchase 2.3M shares at $0.0001/share (~$46M value based on Nov 11 closing price).
- RemeGen eligible for up to $300M in development milestones, including $20M for initial clinical/tech transfer milestones.
- Existing sales milestone and royalty framework (high single-digit to mid-teen % royalties) applies on an aggregated basis.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access